BioSpace News Archive

TransPerfect Life Sciences, a leading provider of technologies and services to support clinical trials and product development for the biopharmaceutical industry, today announced the inaugural summit in its new thought leadership series, C3: Conversations on Clinical Content.

MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed.

UCM Digital Health, a provider of telehealth technology and services, announces a fully integrated, end-to-end, web and app-based solution designed to screen for symptoms of COVID-19, and provide access to a team of medical providers for follow-up care where further assessment, testing, diagnosis and treatment can take place

Advanced Instruments—an innovative developer of scientific and analytical instruments and related services for the biotech industry—announced the latest release to its biotech instrument portfolio, the OsmoTECH XT Single-Sample Micro-Osmometer.

Cytovia Therapeutics, an emerging biopharmaceutical company developing Natural Killer Cell Therapeutics, today announced that it will participate in three key conferences in October 2020.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, announced today that it has commenced an underwritten public offering of its shares of common stock.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the company’s participation at the Digital World CB & CDx meeting which will be held online, September 29-October 1, 2020. Personalis will present “Enabling the Expansive Interrogation of a Tumor & Its Microenvironment from a Single Sample for Translational Research and Precision Medicine ,” featuring the Person

Greenwich LifeSciences, Inc. (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the closing of its initial public offering of 1,260,870 shares of its common stock at a public offering price of $5.75 per share for gross proceeds of $7,250,002, before deductin

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced the commencement of an underwritten public offering of 4,000,000 shares of its common stock.

ILiAD Biotechnologies, LLC (ILiAD) today presented positive topline Phase 2b trial results of its lead pertussis vaccine candidate BPZE1 at the virtual World Vaccine Congress.